GlassScriptPhysician profile
Shant Tomassian
NPI 1215594692
$1,577.23
in general payments reported to CMS, 2019-2025
23 companies · $76.62 in 2025
The $76.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $586 · 2023: $634 · 2024: $281 · 2025: $76.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $190.71 | 2022-2023 | Livalo, Seglentis |
| Stryker Corporation | $161.11 | 2022 | |
| Esperion Therapeutics, INC. | $140.76 | 2022-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.82 | 2022-2024 | Jardiance |
| Gilead Sciences, INC. | $121.07 | 2022-2024 | Veklury |
| Idorsia Pharmaceuticals US INC | $117.93 | 2022 | |
| Lilly USA, LLC | $101.59 | 2022-2024 | Jardiance, Amyvid, Emgality |
| Sumitomo Pharma America, INC. | $68.67 | 2023 | Gemtesa |
| Glaxosmithkline, LLC. | $56.79 | 2023 | Arexvy, Shingrix |
| Novo Nordisk INC | $56.39 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $55.79 | 2023-2024 | |
| Amgen INC. | $53.99 | 2023-2025 | Repatha, Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $48.15 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.88 | 2022-2024 | |
| Exact Sciences Corporation | $42.76 | 2023 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.79 | 2023-2025 | Xifaxan, Trulance |
| Shield Therapeutics INC | $33.72 | 2024 | |
| Ironwood Pharmaceuticals, INC | $29.93 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $21.68 | 2023 | |
| Phadia US INC. | $19.19 | 2022 | |
| Abbvie INC. | $17.55 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.11 | 2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shant Tomassian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.